Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients – FINITE study

Journal of Hepatology

Volumn 67, Issue 5, 2017, Pages 918-924

  Berg, Thomas ^a   Simon, Karl Georg ^b   Mauss, Stefan ^c   Schott, Eckart ^d   Heyne, Renate ^e   Klass, Dietmar M ^f   Eisenbach, Christoph ^g   Welzel, Tania Mara ^h   Zachoval, Reinhart ⁱ   Felten, Gisela ^j   Schulze zur Wiesch, Julian ^k   Cornberg, Markus ^l   Op den Brouw, Marjoleine L ^m   Jump, Belinda ⁿ   Reiser, Hans ⁿ   Gallo, Lothar ^o   Warger, Tobias ^o   Petersen, Jörg ^p  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b Gastroentrologische Gemeinschaftspraxis   (Germany)

^c Zentrum fur HIV und Hepatogastroenterologie   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e Leberzentrum Checkpoint   (Germany)

^f Dept of Neurology   (Germany)

^g Department of Internal Medicine   (Germany)

^h UNIVERSITY HOSPITAL FRANKFURT   (Germany)

ⁱ LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^j Gastroenterologische Gemeinschaftspraxis   (Germany)

^k UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^l HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^m Gilead Sciences Europe Ltd   (United Kingdom)

ⁿ GILEAD SCIENCES   (United States)

^o Gilead Sciences GmbH   (Germany)

^p UNIVERSITY OF HAMBURG   (Germany)

more..

Author keywords

Finite therapy; HBeAg negative; HBsAg loss; Tenofovir disoproxil fumarate

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; TENOFOVIR DISOPROXIL; VIRUS DNA; ANTIVIRUS AGENT; TENOFOVIR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS B; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GERMANY; HEPATITIS B VIRUS; HUMAN; LABORATORY TEST; LIVER CIRRHOSIS; LONG TERM CARE; MALE; MONOTHERAPY; MULTICENTER STUDY; NONHUMAN; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SIDE EFFECT; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VIRUS LOAD; AFTERCARE; DRUG EFFECT; DRUG MONITORING; GENETICS; IMMUNOLOGY; MIDDLE AGED; PROCEDURES; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VIROLOGY;

ADULT; AFTERCARE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG MONITORING; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; TENOFOVIR; TREATMENT OUTCOME; VIRAL LOAD; WITHHOLDING TREATMENT;

EID: 85027707031     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.07.012     Document Type: Article

References (23)

1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis B virus infection. J Hepatol 67 (2017), 370–398, 10.1016/j.jhep.2017.03.021.
2. Liaw, Y.F., Kao, J.H., Piratvisuth, T., Chan, H.L., Chien, R.N., Liu, C.J., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 6 (2012), 531–561.
3. Lok, A., McMahon, B., Chronic hepatitis B. Hepatology 45 (2007), 507–539.
4. Lok, A., McMahon, B., Chronic hepatitis B: update 2009. Hepatology 50 (2009), 661–662.
5. Ridruejo, E., Silva, M.O., Safety of long-term nucleos(t)ide treatment in chronic hepatitis B. Expert Opin Drug Saf 11 (2012), 357–360.
6. Hadziyannis, S.J., Sevastianos, V., Rapti, I., Vassilopoulos, D., Hadziyannis, E., Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology 143 (2012), 629–636.
7. Santantonio, T., Mazzola, M., Iacovazzi, T., Miglietta, A., Guastadisegni, A., Pastore, G., Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 32 (2000), 300–306.
8. Fung, S.K., Wong, F., Hussain, M., Lok, A.S., Sustained response after 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 11 (2004), 432–438.
9. Song, M.J., Song do, S., Kim, H.Y., Yoo, S.H., Bae, S.H., Choi, J.Y., et al. Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B. World J Gastroenterol 18 (2012), 6277–6283.
10. Liaw, Y.F., Jia, J.D., Chan, H.L., Han, K.H., Tanwandee, T., Chuang, W.L., et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology 54 (2011), 1591–1599.
11. Marcellin, P., Bonino, F., Yurdaydin, C., Hadziyannis, S., Moucari, R., Kapprell, H.P., et al. Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. Hepatol Int 7 (2013), 88–97.
12. Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I.M., et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5- year open-label follow-up study. Lancet 381 (2013), 468–475.
13. Piratvisuth, T., Marcellin, P., Pepescu, M., Kapprell, H.P., Rothe, V., Lu, Z.M., Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e-antigen-positive patients. Hepatol Int 7 (2013), 429–436.
14. Chen, C.H., Lu, S.N., Hung, C.H., Wang, J.H., Hu, T.H., Changchien, C.S., et al. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment. J Hepatol 61 (2014), 515–522.
15. Jeng, W.J., Sheen, I.S., Chen, Y.C., Hsu, C.W., Chien, R.N., Chu, C.M., et al. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology 58 (2013), 1886–1896.
16. Chang, M.-L., Liaw, Y.-F., Hadziyannis, S.J., Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther 42 (2015), 243–257.
17. Papatheodoridis, G., Vlachogiannakos, I., Cholongitas, E., Wursthorn, K., Thomadakis, C., Touloumi, G., et al. Discontinuation of oral antivirals in chronic hepatitis B: A systematic review. Hepatology 63 (2016), 1481–1492.
18. Chang, M.L., Liaw, Y.F., Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management. J Hepatol 61 (2014), 1407–1417.
19. Höner Zu Siederdissen, C., Rinker, F., Maasoumy, B., et al. Viral and host responses after stopping long-term nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B. J Infect Dis 15 (2016), 1492–1497.
20. Marcellin, P., Ahn, S.H., Ma, X., Caruntu, F.A., Tak, W.Y., Elkashab, M., et al. Combination of tenofovir disoproxil fumarate and peginterferon α-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology 150 (2016), 134–144.
21. Bourliere, M., Rabiega, P., Ganne-Carrie, N., Serfaty, L., Marcellin, P., Barthe, Y., et al. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy vs. nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial. Lancet Gastroenterol Hepatol 2 (2017), 177–188.
22. Lampertico P, Brunetto MR, Craxi A, Gaeta GB, Rizzetto G, Colombo M, et al. Add-on Peginterferon Alfa-2a significantly reduces HBsAg levels in HBeAg-negative, genotype D chronic hepatitis B patients fully suppressed on nucleot(s)ide analogue treatment The HERMES Study. 50th Annual Meeting of the European Association for the Study of the Liver; April 22–26, 2015; Vienna, Austria; Abstract #LP25.
23. Ning, Q., Han, M., Sun, Y., Jiang, J., Tan, D., Hou, J., et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial (OSST trial). J Hepatol 61 (2014), 777–784.